Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Plaque Psoriasis · Rheumatoid Arthritis · CANF

Can Fite Biopharma

Can-Fite BioPharma

Can Fite Biopharma clinical programs — 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA HQ
9 Employees
Public company Type
CANF · NYSE Ticker
Company details
Status
Public
HQ
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA
Employees
9
Programs
20
Drugs
4
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Can Fite Biopharma projects

20 ClinicalTrials.gov programs sponsored by Can Fite Biopharma.

Can Fite Biopharma has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

20 programs

Clinical programs

  1. CF101

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  2. CF101

    Can-Fite BioPharma

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

  3. CF101 1 mg

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  4. CF101 2mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  5. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  6. Namodenoson

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  7. piclidenoson

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. CF 102

    Can-Fite BioPharma

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  9. CF101

    Can-Fite BioPharma

    Ocular Hypertension

    phase 2 small molecule completed

    1 trial

  10. CF101

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 2 small molecule completed

    3 trials

  11. CF101

    Can-Fite BioPharma

    Uveitis, Posterior

    phase 2 small molecule terminated

    1 trial

  12. CF101

    Can-Fite BioPharma

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  13. CF101 1mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  14. CF102

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    2 trials

  15. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  16. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  17. Namodenoson 25mg

    Can-Fite BioPharma

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  19. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 small molecule completed

    1 trial

  20. Piclidenoson

    Can-Fite BioPharma

    Lowe Syndrome

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Can Fite Biopharma have?

20 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.